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INTRODUCTION
In 2006, the Food and Drug Administration (FDA) approved a vaccine for certain strains
of the human papillomavirus (HPV), the most common sexually transmitted infection (STI) in the
United States.1 The FDA initially approved this vaccine, Gardasil, only for use in females (age
twelve through twenty-six) to prevent cervical cancer and genital warts in females caused by
HPV.2 Merck & Co., the vaccine manufacturer, marketed it to adolescent females and parents
with adolescent daughters as a means of preventing cervical cancer. In 2009, the FDA approved
the use of Gardasil in males for the prevention of genital warts. 3 Although males and females are
equally susceptible to HPV, and equally likely to transmit the disease to a sexual partner, the
focus on cervical cancer prevention precludes the inclusion of males in HPV vaccine media
campaigns and health policies. The concentration on cervical cancer overshadows discussions of
other cancers prevented by the vaccine, and stymies the development of comprehensive HPV

* J.D. 2012, University of Pennsylvania. The author would like to thank Professor Kristen Madison, Sophie Joslin-Roher,
and Samuel Ostroff for their help with this article.
1

Gardiner Harris, U.S. Approves Use of Vaccine for Cervical Cancer, N.Y. TIMES, June 9, 2006, at A1.

2

Id.

3

FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and
Guidance From the Advisory Committee on Immunization Practices, 304 JAMA 518, 518 (2010) [hereinafter FDA
Licensure of HPV Vaccine].
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vaccination policies.
State-mandated vaccinations for school attendance are the most effective means of
vaccinating a population. Supreme Court doctrine supports this policy.4 However, in the case of
HPV, there are impediments to a comprehensive vaccination requirement. Three themes appear
in arguments against HPV vaccinations: (1) legality; (2) vaccine safety; and (3) adolescent
sexuality. First, opponents question the constitutionality of an HPV vaccination mandate because
HPV is not an airborne disease, as are those targeted by most mandated vaccinations. The means
of a disease‟s transmission, however, does not impact its legal analysis, and the Hepatitis B
vaccine is a prime example of a mandated vaccination for a sexually transmitted disease.
Additionally, many oppose such legislation because a required vaccination impinges on parental
autonomy. Although the Supreme Court supports parental autonomy in the upbringing of
children,5 this privilege is not without limit.6 A state‟s right to mandate a vaccination necessarily
infringes on parental autonomy, and is supported by legal precedent because parents are not
allowed to subject their children to harm. 7 Second, opponents question the vaccine‟s long-term
health effects and its general safety. Medical research, though, supports the vaccine‟s safety for
both males and females, and there have been almost no serious adverse events associated with the
vaccine.8 Finally, opponents argue that mandating such a vaccination will increase sexual
activities by giving adolescents a false sense of security about sex, as well as undercut efforts
made by abstinence-only education.9 These are the two most prominent arguments against the
vaccine, but nevertheless also fail. Other cornerstones of safe sex education, like the promotion
of condoms and emergency contraception, have neither increased sexuality activities, nor
undercut efforts by abstinence-only education.10 As this Article will demonstrate, the arguments
attacking the vaccine are flawed, and serve only as impediments to its widespread use.
HPV vaccination conversations need to be shifted away from discussions of adolescent
sexuality, and policies need to include both males and females. This Article argues that focusing
HPV vaccination efforts on females is a mistake with serious health policy consequences. First,
vaccines that target only one segment of the population are not effective at reducing the
prevalence of a communicable disease. Second, current vaccination policies center on
heterosexual transmission of the disease, and thus these policies are exclusivist and ignore men
who have sex with men, a high-risk subgroup for HPV and HPV-related infections, as well as

4

See, e.g., Jacobson v. Massachusetts, 197 U.S. 11 (1905).

See Meyer v. Nebraska, 262 U.S. 390 (1923); Pierce v. Soc‟y of Sisters, 268 U.S. 510, 534–35 (1925)
(asserting that Meyer v. Nebraska stands for the doctrine that parents have the liberty to “direct the upbringing and
education of [their] children . . . .”); see also Wisconsin v. Yoder, 406 U.S. 205, 232 (1972) (“This primary role of the
parents in the upbringing of their children is now established beyond debate as an enduring American tradition.”).
5

6

Prince v. Massachusetts, 321 U.S. 158, 166 (1944).

7

Id.

8

See infra notes 166–183 for more on the safety and long-term efficacy of the HPV vaccine.

9

Lane Wood, A Young Vaccine for Young Girls: Should the Human Papillomavirus Vaccination Be
Mandatory for Public School Attendance?, 20 THE HEALTH LAW. 30, 34 (2007–2008); see also Nancy Gibbs, Defusing
the War over the ―Promiscuity‖ Vaccine, TIME, June 21, 2006, http://www.time.com/time/nation/article/
0,8599,1206813,00.html.
10
See generally Bradley J. Monk & Dorothy J. Wiley, Will Widespread Human Papillomavirus
Prophylactic Vaccination Change Sexual Practices of Adolescent and Young Adult Women in America?, 108 OBSTETRICS
& GYNECOLOGY 420 (2006); see also Amy Bleakley et al., Public Opinion on Sex Education in US Schools, 160 ARCHIVE
OF PEDIATRIC & ADOLESCENT MED. 1151 (2006).
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women who have sex with women. 11 Additionally, current vaccination policies fail to reach lowincome females, who are disparately impacted by HPV and HPV-related cancers. Instead of
focusing exclusively on females, vaccination efforts need to be directed at both males and
females. State-mandated vaccinations for school attendance reduce disease occurrence and are a
legal means of creating population-wide immunity. To ensure maximum coverage, accessibility,
and immunity, this Article calls for an HPV vaccination requirement for school attendance for
both adolescent males and females.
This Article is divided into three parts. Part I examines HPV, the infections caused by
the virus, and the incidence of HPV-related diseases in the United States. This section also
discusses the efficacy of the HPV vaccine. Part II provides reasons for comprehensive
vaccination policies through an examination of the population subgroups ignored by current
vaccination policies. This section examines theories of population (herd) immunity, and speaks to
the issue of whether comprehensive HPV vaccination policies are cost-effective. Part III argues
that mandating the HPV vaccination for male and female adolescents for school attendance is
constitutional and the best way to ensure effective vaccine coverage and adherence. This Article
brings together a variety of issues surrounding the current HPV vaccine controversy in order to
demonstrate that the vaccine is an important health intervention. A school mandate will ensure a
sex-neutral and sexuality-neutral approach to eradicating HPV-related cancers and genital
diseases.
I.

THE HUMAN PAPILLOMAVIRUS
A. Human Papillomavirus & Cancer

Human papillomavirus is the most common sexually transmitted infection (STI) in the
United States,12 infecting over 20 million people.13 HPV is transmitted through sexual contact,
typically during vaginal and anal sex, but can also be transmitted through oral sex and genital-togenital contact (i.e. skin to skin contact).14 According to the National Cancer Society, the only
way to prevent HPV transmission is by abstaining from all sexual activity; more realistically,
having sexual contact with fewer partners or with people who do not have a lot of sexual partners
lowers the risk of HPV infection.15 Condoms are helpful in the prevention of HPV, 16 but because

11

In this article, the terms male and female refer to biological sexes, not genders. I avoid the use of the term
“homosexual” in favor of MSM and WSW because the latter terms are commonly used in medical and public health
discourse.
12
Human Papillomavirus (HPV), CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/hpv/
(last visited Apr. 10, 2012).

Genital HPV Infection – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
std/HPV/STDFact-HPV.htm (last visited Apr. 10, 2012)
13

14

Id.

15

Human Papilloma Virus (HPV), Cancer, and HPV Vaccines: Frequently Asked Questions, AM. CANCER
SOC‟Y, http://www.cancer.org/Cancer/CancerCauses/OtherCarcinogens/InfectiousAgents/HPV/HumanPapillomaVirusand
HPVVaccinesFAQ/hpv-faq-how-common-is-hpv#top (last updated Mar. 22, 2012) [hereinafter HPV FAQs, AM. CANCER
SOC‟Y].
16

Marcia L. Shew et al., Association of Condom Use, Sexual Behaviors, and Sexually Transmitted Infection
with the Duration of Genital Human Papillomavirus Infection Among Adolescent Women, 160 ARCHIVES OF PEDIATRIC &
ADOLESCENT MED. 151, 155 (2006).
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it can be passed from genital-to-genital contact the disease can be transmitted prior to condom
usage.17 Cases of HPV are most prevalent in females in their early twenties, and then tend to
decrease with age.18 By contrast, HPV incidence in males is consistent across age ranges; about
sixty percent of males between the ages of eighteen and seventy have HPV in the United States. 19
There are over one hundred strains of HPV,20 and about forty of these strains infect the
genital area.21 Ninety percent of cases of HPV infection clear up within two years. 22 However,
strains six, eleven, sixteen, and eighteen are considered high-risk because they cause genital
diseases, including cancers and genital warts. 23 Strains sixteen and eighteen cause seventy
percent of all cases of cervical cancer and a significant number of cases of anal, vulva, vaginal,
penile, and throat, head and neck cancers. 24 Additionally, strains six and eleven cause about
ninety percent of all cases of genital warts.25 Genital warts and cervical cancer are the two most
common conditions associated with HPV.26
Approximately five percent of all cancers worldwide are caused by HPV. 27 There is
consensus in research and medical communities that HPV not only causes cervical cancer, but is
responsible for nearly all cases of cervical cancer. 28 According to the American Cancer Society,
in 2010 there were 12,200 women who developed new cases of cervical cancer and 4,210 women
who died from cervical cancer.29 The occurrence rate for cervical cancer is 8.1 per 100,000
females, on average, in the United States. 30 The death rate for cervical cancer is relatively low:
2.4 out of 100,000 females with the disease die from it. 31 Regular pap smears, a routine procedure
that tests for irregular cells on the cervix, have been effective in catching cancerous cells on the
17

HPV FAQs, AM. CANCER SOC‟Y, supra note 15, at 4.

18

See Micah Globerson, Protecting Women: A Feminist Legal Analysis of the HPV Vaccine, 17 TEX. J.
WOMEN & L. 67, 69–70 (2007); Sylvia Law, Human Papillomavirus Vaccination, Private Choice, and Public Health, 41
U.C. DAVIS L. REV. 1731, 1733 (2008).
19

Shari Roan, HPV: Men Can Get it Too, L.A. TIMES, Mar. 19, 2007, at F1; see also ANNA R. GIULIANO ET
CLEARANCE OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN MEN (HIM): A COHORT STUDY 6
(2011) [hereinafter GIULIANO ET AL., INCIDENCE AND CLEARANCE] (asserting that: “Whereas risk of HPV decreases with
increasing age in women, men seem to have a stable risk for acquiring new HPV infections throughout their life.”).
AL., INCIDENCE AND

20

Gail Javitt et al., Assessing Mandatory HPV Vaccination: Who Should Call the Shots?, 36 J. L. MED. &
ETHICS 384, 385 (2008).
21

Genital HPV Infection – Fact Sheet, supra note 13.

22

Id.

23

Javitt et al., supra note 20, at 385.

Id.; see also Hisham Mehanna et al., Head and Neck Cancer – Part I: Epidemiology, Presentation, and
Prevention, 341 BRIT. J. MED. 663, 664 (2010) [hereinafter Mehanna et al., Head and Neck Cancer].
24

25

Javitt et al., supra note 20, at 385.

26

Genital HPV Infection – Fact Sheet, supra note 13.

27

Anil K. Chaturvedi, Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and
Women, 46 J. ADOLESCENT HEALTH S20, S20 (2010).
28

Id. at S21; see also HPV FAQs, AM. CANCER SOC‟Y, supra note 15, at 4.

AM. CANCER SOC‟Y, CANCER FACTS AND FIGURES 2010 4 (2010), available at http://www.cancer.org
/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf [hereinafter CANCER FACTS AND
FIGURES].
29

30
SEER Stat Fact Sheet: Cervical Uteri, NAT‟L CANCER INST., http://www.seer.cancer.gov/statfacts/html
/cervix.html (last visited Apr. 10, 2012).
31

Id.
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cervix at an early stage and preventing the development of cervical cancer. 32 Some argue that
there is no need for a vaccine, because regular exams and screenings, when available, are
effective, less costly, and do not involve shots. 33
Although pap smears are effective at preventing cervical cancer, they do not screen for
all cancers caused by HPV infection, and the rates and prevalence of these other cancers are not
insignificant. HPV causes eighty to ninety percent of anal cancers, which is a growing problem in
the United States, affecting males and females alike. Between 1994 and 2000, anal cancer
occurrence increased for both males and females. 34 In 2010, there were an estimated 5,000 new
cases of anal cancer in the United States: 2,000 new cases among males, and 3,000 among
females.35 The incidence rate is 1.6 per 100,000 males and females per year. 36 The death rate
from anal cancer is 0.2 per 100,000 individuals, both males and females.37 Females who have
HPV-related cervical or vulva cancer are at a higher risk for anal cancer because of previous
exposure to cancerous HPV infection. 38 Most cases of anal cancer are found in men who have sex
with men (MSM) and in females who have sex with males. However, studies show that there is a
growing presence of anal cancer among males who have sex with females, which raises questions
about how this particular disease develops once HPV is transmitted. 39
In addition to cervical and anal cancer, HPV also causes an estimated forty to sixty-four
percent of vaginal cancer cases, and forty to fifty-one percent of vulva cancer cases in females.40
In 2010, there were an estimated 2,300 new cases of vaginal cancer and 3,900 new cases of vulva
cancer.41 For vulva cancer, there is an occurrence rate of 2.4 per 100,000 females in the United
States, and a death rate of approximately 0.5 per 100,000 females. 42 The National Cancer
Institute does not compile occurrence data on vaginal cancer because it is considered a rare
cancer. HPV also causes thirty-six to forty percent of penile cancer cases. 43 In 2010, there were
an estimated 1,250 new cases of penile cancer in the United States. Finally, HPV has also been
found to cause throat, head and neck cancers.44 Of the 49,200 new cases of throat cancer in the
32
Chaturvedi, supra note 27, at S23; see also Eliav Barr et al., Impact of a Prophylactic Quadrivalent
Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle Vaccine in a Sexually Active Population of North
American Women, 198 AM. J. OBSTETRICS & GYNECOLOGY 261.e1, 261.e1 (2008).
33
Judy Peres, Who Should Get the HPV Vaccine? Usage Expands Amid Debate, 102 J. NAT‟L CANCER
INST. 838, 840 (2010).
34
Djenaba A. Joseph et al., Understanding the Burden of Human Papillomavirus Associated Anal Cancers
in the United States, 113 CANCER 2892, 2892–93 (2008); see generally, Lisa G. Johnson et al., Anal Cancer Incidence and
Survival: The Surveillance, Epidemiology, and End Results Experience, 1973 – 2000, 101 CANCER 281 (2004) (explaining
trends in the incidence of anal cancer for various groups over time).
35

CANCER FACTS AND FIGURES, supra note 29, at 4.

36

SEER Stat Fact Sheet: Cervical Uteri, supra note 30.

37

Id.

38

Joseph et al., supra note 34, at 2893.

39

Alan G. Nyitray et al., Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Men
who have Sex with Women: A Cross National Study, 201 J. INFECTIOUS DISEASES 1498, 1504 (2010).
40

Chaturvedi, supra note 27, at S21 (citing studies conducted in 2006 and 2008).

41

CANCER FACTS AND FIGURES, supra note 29, at 4.

42

SEER Stat Fact Sheet: Cervical Uteri, supra note 30.

43

Nyitray et al., supra note 39, at 1504.

See generally Gypsyamber D‟Souza et al., Case–Control Study of Human Papillomavirus and
Oropharyngeal Cancer, 356 NEW ENG. J. MED. 1944 (2007) (finding a strong association between oral HPV infection and
44

Published by Penn Law: Legal Scholarship Repository, 2012

CHERKIN_FINAL[1].DOCX (DO NOT DELETE)

480

4/30/2012 5:33 PM

UNIV. OF PENNSYLVANIA JOURNAL OF LAW AND SOCIAL CHANGE

[Vol. 15

United States in 2010,45 HPV caused about twelve to sixty percent.46 According to the British
Journal of Medicine, head and neck cancer is the sixth most prevalent cancer in the world.47
Incidences of these cancers are increasing in the United States, and researchers attribute this
increase to HPV.48
In addition to cancer, high-risk strains of HPV also cause genital warts.49 Every year in
the United States, about 500,000 people acquire genital warts50 and ninety percent of all cases of
genital warts are attributed to HPV infection. 51 Genital warts afflict both males and females, but
typically have a longer duration of infection in males. 52 Although the medical effects of genital
warts are relatively limited, many doctors cite the psychological affects, such as stress and
embarrassment, as more serious consequences of the disease.53 Recurrence of genital warts is
also quite common.54 Additionally, the HPV strains that cause genital warts can also lead to
recurrent respiratory papillomatosis (RRP), a disease that can restrict airways and result in
multiple surgeries.55
Not surprisingly, because cervical cancer is the most significant consequence of HPV,
HPV is viewed as a female problem, and specifically a heterosexual female problem. 56 Males are
typically perceived as transmitters of the infection who increase the cervical cancer risk in
females, but they are not perceived as personally at risk.57 This perception is incorrect. While the
majority of males who contract HPV are asymptomatic, HPV does lead to negative health

cancer of the throat).
45

CANCER FACTS AND FIGURES, supra note 29, at 4.

46

Chaturvedi, supra note 27, at S21. The statistics for throat cancer are harder to determine because of the
other risk factors associated with the disease, including tobacco inhalation and alcohol consumption, can also be present.
CANCER FACTS AND FIGURES, supra note 29, at 17. Additionally, researchers found that HPV-related neck and head
cancer are significantly different than other types of these cancers. See Mehanna et al., Head and Neck Cancer, supra note
24, at S21 (“HPV related oropharyngeal carcinoma is a distinct disease entity. Patients are younger (usually 40-50 years
old), often do not report the usual risk factors of smoking or high alcohol intake, and often present with a small primary
tumour and large neck nodes.”).
47
Hishman M. Mehanna, Oropharyngeal Carcinoma Related to Human Papillomavirus, 340 BRIT. J. MED.
879, 879 (2010) [hereinafter Mehanna, Oropharyngeal Carcinoma].
48

Id.

49

Anna R. Giuliano et al., Epidemiology and Pathology of HPV Disease in Males, 117 GYNECOLOGIC
ONCOLOGY S15, S15 (2010) [(hereinafter Giuliano et al., Epidemiology of HPV].
50

Jan Hoffman, Vaccinating Boys for Girls’ Sake?, N.Y. TIMES, Feb. 24, 2008, at ST1, ST10.

Sexually Transmitted Disease Treatment Guidelines 2010 – Genital Warts, CTRS. FOR DISEASE CONTROL
& PREVENTION, http://www.cdc.gov/std/treatment/2010/genital-warts.htm (last visited Apr. 10, 2012).
51

52

Anna R. Giuliano, Human Papillomavirus Vaccination in Males, 170 GYNECOLOGIC ONCOLOGY S24,
S25 (2007) [hereinafter Giuliano, HPV Vaccination].
53

Hoffman, supra note 50, at ST10; see also Giuliano et al., Epidemiology of HPV, supra note 49, at S15.

54

Giuliano et al., Epidemiology of HPV, supra note 49, at S15.

55

Gregory D. Zimet, Potential Barriers to HPV Immunization: From Public Health to Personal Choice, 35
AM. J. L. & MED. 389, 389 (2009) [hereinafter Zimet, Potential Barriers].
56

See infra notes 91–102 for data on HPV and HPV-related diseases among women who have sex with

women.
Joel M. Palefsky, Human Papillomavirus-Related Disease in Men: Not Just a Women’s Issue, 46 J.
ADOLESCENT HEALTH S12, S12 (2010).
57
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consequences in males, including anal, penile, and throat cancers, and genital warts. 58 HPV in
males, because it is mostly undetected and thus untreated, can weaken immune systems, and some
data suggests that it makes affected males more susceptible to HIV. 59 HPV is particularly
problematic in the MSM population, whose members are seventeen times more likely to contract
HPV than males who only have sex with females.60 The risk of developing HPV-related diseases
is also significantly higher in this segment of the male population. 61
HPV is widely assumed to be a relatively harmless STI. However, the high-risk strains
of the disease are not. HPV is a serious public health issue. The HPV vaccine offers an avenue
for cancer and disease reduction, and thus should be used with more frequency to prevent the
spread of the high-risk strains of HPV.
B. The HPV Vaccine: Quadrivalent Gardasil
In June 2006, the Food and Drug Administration (FDA) approved Merck‟s Gardasil, a
quadrivalent HPV vaccine that protects against strains six, eleven, sixteen, and eighteen of HPV
for the prevention of cervical cancer and genital warts in females only. 62 For females, studies
from drug trials showed that the quadrivalent vaccine significantly reduced the occurrence of
genital cancerous lesions and genital warts.63 In some studies, the vaccine was proven nearly
100% effective in preventing the genital diseases associated with HPV in females.64 In October
2009, the FDA approved Cervarix, a bivalent HPV vaccine manufactured by GlaxoSmithKline
Biologicals, for use in females for the prevention of cervical cancer caused by HPV strains sixteen
and eighteen.65 Although this Article‟s arguments and conclusions are relevant for Cervarix, this
Article will focus on Gardasil, the quadrivalent vaccine, for two main reasons: (1) most of the
clinical research has been conducted on the quadrivalent vaccine; and (2) as of February 2012,
Cervarix has not yet been approved for use in males.
In October 2009, the FDA approved Gardasil for males, aged nine through twenty-six,
for the prevention of genital warts caused by HPV strains six and eleven. 66 In drug trials on
males, the quadrivalent vaccine demonstrated high levels of efficacy in reducing the occurrence of
HPV & Men – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/std/hpv/
stdfact-hpv-and-men.htm (last visited Apr. 10, 2012) [hereinafter CDC, HPV & Men].
58

59
Palefsky, supra note 57, at S12 (“[R]ecent data suggests that HPV infection in men may increase the risk
of acquiring human immunodeficiency virus (HIV) infection.”). HPV is also a serious health problem for HIV-positive
individuals. However, this article focuses only on HIV-negative segments of the population.
60

See CDC, HPV & Men, supra note 58.

61

See Jane J. Kim, Targeted Human Papillomavirus Vaccine of Men Who Have Sex with Men in the USA: a
Cost-Effectiveness Modelling Analysis, 10 LANCET INFECTIOUS DISEASES 845 (2010) (discussing the risks of anal cancer,
developed from HPV, in MSM) [hereinafter Kim, Targeted HPV Vaccine].
62

See Harris, supra note 1; see also GARDASIL, http://www.gardasil.com/ (last visited Apr. 10, 2012).

63

Barr et al., supra note 32, at 261.e1 (2008) (describing studies conducted on North American women); see
also Suzanne M. Garland et al., Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases,
356 NEW ENG. J. MED. 1928, 1935 (2007) (describing studies conducted on women across the world).
64

Garland et al., supra note 63, at 1935.

65

Press Release, Food & Drug Admin., FDA Approves New Vaccine for Prevention of Cervical Cancer
(Oct. 16, 2009), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm (last
visited Apr. 10, 2012).
66

FDA Licensure of HPV Vaccine, supra note 3, at 518.
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genital cancerous lesions and genital warts. 67 Although the vaccine did have lower rates of
efficacy in males than in females, it was shown to reduce the rate of HPV infection in males by
sixty-five percent.68 While early approvals of the use of Gardasil were based on its use to help
prevent cervical cancer in females and genital warts in males, it is now recognized as efficacious
in preventing anal cancer as well. In December 2010, the FDA approved Gardasil for the
prevention of anal cancer in both sexes. 69
The use of Gardasil is strongly supported by federal agencies. The Advisory Committee
in Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention
(CDC) and the Department of Health and Human Services (HHS), recommended the
administration of the vaccine for both males and females. The ACIP is a crucial part of state and
federal vaccination policies. The ACIP is an external, non-partisan group, made up of fifteen
medical experts not employed by the United States government, that issues policy
recommendations to the CDC and HHS.70 The ACIP was formed in 1964 to provide outside
expert advice and guidance to the CDC and HHS on the use of vaccines in civilian populations.71
ACIP recommendations dictate national vaccination policy and play an essential role in the
control of contagious diseases in the United States. ACIP recommendations reach beyond the
federal government, and are largely followed by states in determining vaccination policies.72 In
2009, the ACIP recommended routine administration of the HPV vaccine for females. When the
ACIP first approved the HPV vaccine for males, the group gave a somewhat “lesser”
recommendation for males, while still asserting that the vaccine may be given to males. 73
However, in October 2011, the ACIP changed their recommendation, and now recommends
routine administration of the HPV vaccine for boys. 74 The ACIP advocated for the availability of
Gardasil to males and females through Vaccines for Children, 75 a federal program that funds
routine vaccinations for children who are unable to afford the vaccine. 76
As discussed previously, the HPV vaccine is effective in preventing HPV and helping to
avoid HPV-related health conditions. For the vaccine to be the most effective, however, it must
67

Anna R. Giuliano et al., Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in
Males, 364 NEW ENG. J. MED. 401, 409 (2011) [hereinafter Giuliano, HPV Vaccine in Males].
68

Id.

69

Press Release, Food and & Drug Admin., FDA: Gardasil Approved to Prevent Anal Cancer (Dec. 22,
2010) available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm; see also Jane J.
Kim, Weighing the Benefits and Costs of HPV Vaccination of Young Men, 364 NEW ENG. J. MED. 393, 394 (2011)
(exploring the societal and health cost and benefits of providing the HPV vaccine to young men).
70

Jean C. Smith et al., Immunization Policy Development in the United States: The Role of the Advisory
Committee on Immunization Practices, 150 ANNALS INTERNAL MED. 45, 45 (2009).
71

Id.

72

Amber Oleson, Legislative Update: Should the Human Papillomavirus Vaccine be Mandated for PreAdolescent Girls? The HPV Vaccine Becomes a Political Issue, 28 CHILD. LEGAL RTS. J. 64, 66 (2008).
73

FDA Licensure of HPV Vaccine, supra note 3, at 518.

74

Gardiner Harris, Panel Endorses HPV Vaccine for Boys of 11, N.Y. TIMES, Oct. 26, 2011, at A1.

75

N. Liddon et al., Provider Attitudes Towards HPV Vaccines for Males, 47 J. ADOLESCENT HEALTH 1, 1
(2010); see also Lauri E. Markowitz et al., Quadrivalent Human Papillomavirus Vaccine: Recommendations of the
Advisory Committee on Immunization Practices (ACIP), 56 MORBIDITY & MORTALITY WEEKLY REPORT 1, 16 (2007),
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm?s_cid=rr5602a1_e.
76

Vaccines for Children Program, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
vaccines/programs/vfc/default.htm (last visited Apr. 10, 2011).
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be administered before any HPV exposure.77 As a prophylactic drug, and not a therapeutic one,
Gardasil is only effective in preventing certain strains of HPV, and not treating them once
acquired.78 Due to the time sensitive nature of Gardasil, many argue it should be mandated to
ensure timely adherence.79 Additionally, it is argued that the focus of any HPV vaccination
policies should be on adolescents to ensure that they are immunized prior to HPV exposure. The
next section of this Article demonstrates why both males and females need to be included in any
routine, comprehensive vaccination policy in order to better immunize the population against the
high-risk strains of HPV.
II. WHY AN INCLUSIVE HPV VACCINATION POLICY IS NECESSARY
Current HPV vaccination policies are exclusive and woefully ineffective. At the
moment, the HPV vaccine administration targets only females and has not reduced occurrences of
HPV across the population. The narrow focus of HPV vaccination policies on females is
problematic because the vaccine is not achieving desired population-level immunity. This
ineffectiveness stems from the fact that these policies explicitly fail to include all males,
specifically men who have sex with men, and implicitly exclude certain subgroups of females,
including low-income females and women who have sex with women. This section examines the
problems with current vaccination policies by highlighting the exclusion of certain subgroups of
the population, and by discussing concepts of population-wide immunity and the failures of other
vaccines that targeted only certain segments of the population. This section will demonstrate why
comprehensive and inclusive vaccination programs that target all members of the population will
be the most effective means of reducing the occurrence of HPV and HPV-related cancers in the
United States.
A.

Ignored Subgroups

Current vaccination policies fail to include three particular subgroups of the population:
men who have sex with men (MSM); women who have sex with women (WSW); and lowincome women, particularly those of color. MSM and WSW are both excluded from current
vaccination policies because of the focus of such policies on the heterosexual transmission of the
disease. Although MSM are a high-risk population for HPV, there are many barriers to successful
administration of the vaccine without a formal vaccination mandate. Dr. Jane Kim of the Harvard
School for Public Health argues that “[s]everal obstacles challenge early uptake in this high-risk
subgroup, including age at which people self-identify as MSM [and] willingness to disclose
sexual identity to others,”80 all of which prevent the administration of the vaccine prior to HPV
exposure. The fact that this vaccine is one that must be requested further places the HPV vaccine
out of reach for many low-income women because of the lack of comprehensive reproductive
health services available to this population. Thus, as is evidenced by this section, a sexualityneutral vaccination policy, accompanied with easy accessibility, is essential for the success of the
HPV vaccine.
77

HPV FAQs, AM. CANCER SOC‟Y, supra note 15, at 8–9.

78

Wood, supra note 9, at 31.

Law, supra note 18, at 1764 (“[Y]oung people are far more likely to receive a timely vaccination prior to
contracting the virus if vaccination is mandatory.”).
79

80

Kim, Targeted HPV Vaccine, supra note 61, at 850.

Published by Penn Law: Legal Scholarship Repository, 2012

CHERKIN_FINAL[1].DOCX (DO NOT DELETE)

484

4/30/2012 5:33 PM

UNIV. OF PENNSYLVANIA JOURNAL OF LAW AND SOCIAL CHANGE

1.

[Vol. 15

Men Who Have Sex with Men

The current focus on females for the administration of the HPV vaccine completely
ignores an entire population of men who have sex with men. MSM have a higher risk for HPVrelated genital warts and anal cancer compared to males who only have sex with females. 81 MSM
also have a greater risk for anal cancer than the population in general. 82 The risk and prevalence
of anal cancer in the MSM population is arguably higher than cervical cancer for females in the
United States.83 Although this can be attributed to the high prevalence of vaginal pap smears and
cervical cancer screenings for females, 84 and the relative lack of anal pap smears for males,85 it
highlights the dangers of HPV-related cancers for males in this subgroup. Additionally, unlike
incidences of cervical cancer, which tend to decrease as females age, incidences of anal cancer
remain constant throughout the sexual lifespan of MSM. 86
Mandating the vaccination is the most effective and efficient means of protecting the
MSM subgroup because the mere availability of the vaccine will not ensure appropriate use for
this segment of the population. Many studies show that MSM do not openly admit their sexual
preferences until almost two years after their first sexual contact and after having a number of
sexual partners.87 This affects the efficacy of administering the vaccine to MSM because the drug
must be administered prior to exposure to HPV for maximum effectiveness. 88 Targeting this
subgroup for voluntary vaccination would be futile because the drug needs to be administered
prior to exposure, and would be ineffective, and a waste of resources, to administer the vaccine to
a population that has already been exposed to HPV. 89 One researcher for the National Cancer
Institute argued that the vaccine should be offered to all males because “it‟s impossible to know
which preadolescent boys will grow up to become men who have sex with men, [and thus] it
would not be feasible to target the vaccine to that subgroup of males.” 90
2.

Women Who Have Sex with Women

Discourse around female sexual health focuses on heterosexual females, and there is
documented evidence that WSW do not receive the same level of sexual health care as
81

CDC, HPV & Men, supra note 58; see also Paul L. Reiter et al., Acceptability of HPV Vaccine Among a
National Sample of Gay and Bisexual Men, 37 SEXUALLY TRANSMITTED DISEASES 197, 197 (2010).
82

Reiter et al., supra note 81, at 197.

Marian Pitts et al., What do Gay Men Know About Human Papillomavirus? Australian Gay Men’s
Knowledge and Experience of Anal Cancer Screening and Human Papillomavirus, 34 SEXUALLY TRANSMITTED
DISEASES 170, 170 (2007). Although Pitts‟ data focuses on Australia, the main ideas of her article are applicable to the
United States as well because of Australia‟s status as a Western country that regularly employed vaginal pap smears and
cervical cancer screenings for females.
83

84

Chaturvedi, supra note 27, at S23; see also Barr et al., supra note 32, at 261.

85

Pitts et al., supra note 83, at 171–72.

86

Peter V. Chin-Hong et al., Age-Related Prevalence of Anal Cancer Precursors in Homosexual Men: The
EXPLORE Study, 97 J. NAT‟L CANCER INST. 896, 904 (2005).
87
D. Simatherai et al., What Men Who Have Sex With Men Think About the Human Papillomavirus Vaccine,
85 SEXUALLY TRANSMITTED INFECTION 148, 149 (2009).
88

Id.

89

Id.

90

Peres, supra note 33, at 840.
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heterosexual females. Feminist scholars posit “medicine constitutes a particularly powerful
instrument of support for the coercive institution of heterosexuality.” 91 Sexual health policies
typically focus on heterosexual females, and the heterosexual transmission of STIs. There are an
estimated 2.3 million females in the United States who self-identify as WSW.92 Sex between
females is typically viewed as safer, and thus, WSW do not typically view themselves as at risk
for HPV.93 However, studies demonstrate that WSW do have similar risk levels for, and
incidences of, HPV and cervical cancer as heterosexual females.94 About thirteen percent of
WSW are infected with some strain of HPV.95 HPV can be transmitted through oral and vaginal
sex between females, particularly when sex toys are shared. 96 Additionally, studies have shown
that HPV is transmitted from skin-to-skin contact so that penetration is not a necessary act for
acquiring the disease.97 One study asserted that it is a “popular misconception that lesbians are at
a decreased risk for cervical cancer compared to heterosexual women.” 98 Because of this
misconception, there are fewer WSW who get yearly pap smears, 99 and thus such females are
more at risk for cervical cancer because pap smears are proven to be effective at catching the
disease early. Scholars argue that WSW “often avoid accessing health care because of real or
perceived homophobia and heterosexism . . . [t]herefore, routine screenings are not performed and
cancers may be detected at later, less treatable stages.” 100 Medical professionals assert that WSW
need to be encouraged to have regular pap smears, just as heterosexual females are encouraged to
do so yearly.101 Genital warts can also affect the WSW subgroup; however, the prevalence of this
infection is significantly lower than among heterosexual females and males, and the MSM
subgroup.102 By creating vaccination policies that are universal and sex- and sexuality-neutral,
91
Virginia Braun & Nicola Gavey, ―Bad Girls‖ and ―Good Girls‖?: Sexuality and Cervical Cancer, 22
WOMEN‟S STUD. INT‟L FORUM 203, 209 (1999) (citing SUSAN SHERWIN, NO LONGER PATIENT: FEMINIST ETHICS AND
HEALTH CARE 213 (1992)).
92

Jeanne M. Marrazzo & Kathleen Stine, Reproductive Health History of Lesbians: Implications for Care,
190 AM. J. OBSTETRICS & GYNECOLOGY 1298, 1298 (2004).
93

Lisa Eaton et al., Perceived Prevalence and Risks for Human Papillomavirus (HPV) Infection among
Women Who Have Sex with Women, 17 J. WOMEN‟S HEALTH 75, 80 (2008).
94
See generally Jeanne M. Marrazzo et al., Genital Human Papillomavirus Infection in Women Who Have
Sex With Women, 178 J. INFECTIOUS DISEASES 1604 (1998) (finding that HPV is common among women who have sex
with women even if they have not had sex with men).
95

Eaton et al., supra note 93, at 76.

Jennifer Power et al., Absent Sexual Scripts: Lesbian and Bisexual Women’s Knowledge, Attitudes and
Actions Regarding Safer Sex and Sexual Health Information, 11 CULTURE, HEALTH & SEXUALITY 67, 69 (2009) (citing a
study conducted in 2000).
96

97
Luisa Lina Villa, Prophylactic HPV Vaccines: Reducing the Burden of HPV-Related Diseases, 24
Supplement 1 VACCINE S1/23, S1/23 (2006) (“HPV DNA has been reported in approximately 20% of women who have
never had vaginal intercourse, suggesting that abstaining from penetrative intercourse is not completely protective against
infection.”).
98
Jessica P. Brown & J. Kathleen Tracey, Lesbians and Cancer: An Overlooked Health Disparity, 19
CANCER CAUSES & CONTROL 1009, 1016 (2008).
99
Jeanne M. Marrazzo, Genital Human Papillomavirus Infection in Women Who Have Sex with Women: A
Concern for Patients and Providers, 14 AIDS PATIENT CARE & STDS 447, 449 (2000).
100

Carolee Polek & Thomas Hardie, Lesbian Women and Knowledge about Human Papillomavirus, 37
ONCOLOGY NURSING FORUM E191, E196 (2010).
101

Marrazzo et al., supra note 94, at 1608.

102

See generally JV Bailey et al., Sexually Transmitted Infections in Women Who Have Sex With Women, 80
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the vaccine will reach all females. Vaccination campaigns and policies that focus on heterosexual
sex and transmission adversely affect WSW and are simply bad health policies.
3.

Low Income Females

Mandating the vaccination will not only create a sexuality-neutral policy, but also a raceneutral and income-neutral policy. Studies show that low-income populations have higher rates
of sexually transmitted infections.103 Women of color in the United States are more likely to be in
this subgroup, many of whom are uninsured and have less access to cervical cancer screenings
and regular pap smears.104 African American females and Hispanic females have a greater
likelihood of having cervical cancer105 and also have a significantly higher risk of death from the
disease than Caucasian females.106 Mandating the vaccination will protect low-income
populations and prevent racial minorities from experiencing a negative disparate impact from the
burdens of HPV because the vaccine will be more readily accessible. 107 Although it is argued that
low-income adolescents can get the vaccine through the Vaccines for Children program, the only
way to ensure universal coverage is to mandate the vaccination because this will ensure that all
members of the population receive the vaccine. 108
B.

Herd Immunity

Vaccines are more effective when given to both sexes, because as more people get
vaccinated, the general immunity of the entire population (i.e. the herd) increases.109 Herd
immunity is “the population-level consequence of acquired immunity among some individuals
that can reduce the risk of acquiring infection among susceptible individuals.” 110 Herd immunity
is the goal of all mass immunization programs and is based on the belief that immunizing a
certain portion of the population will create general immunity throughout the population at
large.111 Herd immunity protects persons who have and have not been immunized. Those who

SEXUALLY TRANSMITTED INFECTIONS 244 (2004) (finding that it is possible for sexually transmitted diseases to occur
between women); Katherine Fethers et al., Sexually Transmitted Infections and Risk Behaviours in Women Who Have Sex
With Women, 76 SEXUALLY TRANSMITTED INFECTIONS 345 (2000) (finding higher STD transmission among women who
have sex with women than the control population of the study).
103
Sara E. Forhan et al., Prevalence of Sexually Transmitted Infections Among Female Adolescents Aged
14-19 in the United States, 124 PEDIATRICS 1505, 1510 (2009).
104

Law, supra note 18, at 1764–65.

105

Id. at 1765 (finding Hispanic women have the highest rates of cervical cancer and that African American
women are fifty percent more likely to experience cervical cancer than white women).
106

Globerson, supra note 18, at 73.

107

See Law, supra note 18, at 1764 (stating that a disproportionate number of women of color will die
unnecessarily if they are not vaccinated at a young age).
108

Wood, supra note 9, at 34.

109

Palefsky, supra note 57, at S16; see also Gregory D. Zimet & Susan L. Rosenthal, HPV Vaccine and
Males: Issues and Challenges, 117 GYNECOLOGIC ONCOLOGY S26, S29 (2010) (stating that gender-based vaccinations
policies are less effective and more confusing to the public).
110
Geoffrey P. Garnett, Role of Herd Immunity in Determining the Effect of Vaccines against Sexually
Transmitted Disease, 191 J. INFECTIOUS DISEASES S97, S98 (2005).
111

Id. at S98; see also Javitt et al., supra note 20, at 388.
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are susceptible are protected because high levels of population immunity reduce the likelihood
that a susceptible person will come into contact with another susceptible person or someone
carrying the disease.112
Herd immunity is central to arguments for mandating vaccines in general, 113 and for the
HPV vaccine, in particular. The ultimate goal of any vaccination program is the complete
eradication of the intended disease. However, policymakers and medical professionals
acknowledge that this is an impossible goal, 114 and thus, strategic control of the disease is the
focus of vaccination policies. High vaccine coverage is necessary for herd immunity. 115
Although there are varying thresholds for population-level immunity for any given infectious
disease, the basic premise behind herd immunity is to vaccinate as many members of the
population as possible to create the highest attainable level of general immunity. 116
Some argue that if all females are vaccinated, then males will be covered by herd
immunity as well. However, this argument fails. For cervical cancer prevention, specifically,
many researchers and physicians agree that it is important to vaccinate males to prevent the
transmission of HPV to females117 because studies have shown that the transmission of HPV from
males to their female partners leads to a significant number of cervical cancer cases. 118
Studies of other infectious diseases demonstrate that vaccinating only one segment of the
population does not decrease disease incidence, and in some cases actually increases transmission
overall.119 Two prime examples are the Rubella and Hepatitis B vaccines. These two vaccination
policies failed because both were initially introduced to only a segment of the population and
were unsuccessful at reducing the occurrence of the disease. The Rubella vaccine was initially
offered to only females, to protect them from the dangers of the disease during pregnancy. 120
However, these female-only policies neither lowered the incidence rates of Rubella nor created
generally immunity. It was not until the Rubella vaccine was given to the general population,
through state vaccination mandates, that the disease was basically eradicated. 121
When the FDA approved the Hepatitis B vaccine, it was only offered to certain segments
of the population, and consequently, the prevalence of the disease remained high. 122 A reduction

112

Garnett, supra note 110, at S98.

113

Id. at S98.

114

Paul Fine et al., ―Herd Immunity‖: A Rough Guide, 52 CLINICAL INFECTIOUS DISEASES 911, 914 (2011).

115

Giuliano, HPV Vaccination in Males, supra note 67, at S26.

116

Fine et al., supra note 114, at 914–15.

117

Thomas W. Weiss et al., Human Papillomavirus Vaccination of Males: Attitudes and Perceptions of
Physicians Who Vaccinate Females, 47 J. ADOLESCENT HEALTH 3, 9 (2010).
118

Giuliano, HPV Vaccination in Males, supra note 67, at S25 (citing studies that show that cervical cancer
in females with one lifetime sexual partner is typically caused by HPV transmission by the male‟s partner, and that
promiscuity in males greatly increases risks of cervical cancer in females).
119

Id. at S25–26.

120

Id.

121

Id.; see also Jennifer Caseldine-Bracht, The HPV Vaccine Controversy: Where are the Women? Where
are the Men? Where is the Money?, 3 INT‟L J. FEMINIST APPROACHES TO BIOETHICS 99, 104 (2010) (“When the rubella
vaccine was introduced in the 1960s, it was originally recommended that only women of child-bearing age get inoculated.
However, only when both boys and girls got the vaccine was rubella finally eradicated.”).
122

Sheila M. Rothman & David J. Rothman, Marketing HPV Vaccine: Implications for Adolescent Health
and Medical Professionalism, 302 JAMA 781, 782 (2009).
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in Hepatitis B only occurred after states adopted universal vaccination policies. 123 The
experiences of the Rubella and Hepatitis B vaccines demonstrate that vaccination polices are
neither an effective means of reducing the prevalence of disease nor are they successful at
establishing herd immunity when one segment of the population is targeted. Males need to be
included in vaccination policies to establish an effective level of herd immunity, which will stop
the spread of HPV, and thus reduce the incidences of HPV-related cancer and genital disease.
Some experts have questioned whether it is cost-effective to vaccinate males in addition
to females. Gardasil is the most expensive vaccine recommended by the ACIP,124 and all three
doses of the shot cost about $360 per person.125 Although many studies suggest that vaccinating
males is not cost-effective, these studies only look at cervical cancer prevention and fail to include
cancers and infections that affect males.126 A 2010 study demonstrated that it is cost-effective to
include males in vaccination programs when focusing on the benefits to males and females and
including all cancers and infections caused by HPV in the analysis. 127 This inclusive study
concluded that when the focus is expanded beyond cervical cancer, it is cost-effective to vaccinate
both males and females. Moreover, current studies on the cost-effectiveness of the vaccine for
both males and females focus solely on heterosexual transmission of the disease between males
and females and fail to include the benefits of the vaccine for men who have sex with men (MSM)
and women who have sex with women (WSW).128 These studies also fail to include current
research on the increase of HPV-related anal cancer and head and neck cancer.129 However,
123

Daniel B. Fishbein et al., New, and Some Not-so-New, Vaccines for Adolescents and Diseases They
Prevent, 121 PEDIATRICS S5, S10 (2008).
124

Law, supra note 18, at 1748.

125

Elissa Mendenhall, Guard Against Gardasil, 142 MOTHERING MAGAZINE May–June 2007, at 45, 49.

126

See, e.g., Jane J. Kim & Sue J. Goldie, Health and Economic Implications of HPV Vaccination in the
United States, 359 NEW ENG. J. MED. 821, 821 (2008) (asserting that it would be cost-effective to vaccinate only females
for the benefit of the entire population, assuming there was a high proportion of vaccinated females); see also Harrell W.
Chesson et al., Cost-Effectiveness of Human Papillomavirus Vaccine in the United States, 14 EMERGING INFECTIOUS
DISEASE 244, 247 (2008) (demonstrating that the vaccine is highly cost-effective when focusing only on the benefit to
females); Zimet, Potential Barriers, supra note 55, at 397 (describing the problems with most cost-benefit analysis models
that focus solely on cervical cancer).
127

Elamin H. Elbasha & Erik J. Dasbach, Impact of Vaccinating Boys and Men Against HPV in the United
States, 28 VACCINE 6858, 6858 (2010). To date, there are no cost-benefit studies of the HPV vaccine for all males, both
who have sex with females and who have sex with males. Significantly, a recent study of the incidence of HPV in males,
which demonstrated high occurrence of HPV in males, concluded that more information about the prevalence and
epidemiology of the infection is necessary for any “realistic cost-effectiveness” study to be conducted. See generally
GIULIANO ET AL., INCIDENCE AND CLEARANCE, supra note 19.
128

See Harrell Chesson, HPV Vaccine Cost-Effectiveness: Updates and Reviews, CTRS. FOR DISEASE
CONTROL & PREVENTION, ADVISORY COMM. ON IMMUNIZATION PRACTICES 23 (Feb. 24, 2011), www.cdc.gov/vaccines
/recs/acip/ downloads/mtg-slides... /11-4-hpv-cost.pdf (asserting that the study relied on by the ACIP and CDC is limited
because it only focuses on heterosexual HPV transmission between females and males). See also Jane J. Kim & Sue J.
Goldie, Cost Effectiveness Analysis of Including Boys in a Human Papillomavirus Vaccination Programme in the United
States, BRIT. MED. J., Oct. 9, 2009, at 7.
A limitation of our analysis is that we only represented heterosexual partnerships and therefore did
not reflect HPV transmission among men who have sex with men, who face a high risk of anal
cancer and may realise [sic] a greater benefit from HPV vaccination. Such an analysis would
require a more comprehensive model that includes a fuller range of sexual behaviours [sic] . . . .
129

Mehanna, Oropharyngeal Carcinoma, supra note 47, at 880.
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separate studies demonstrate that the vaccine is highly cost-effective for the MSM group,
especially when focusing on both anal cancer and genital warts. 130
Current HPV vaccination policies, which target only females, are heteronormative,
unfair, and ineffective. Additionally, these policies fail to achieve herd immunity. Universal
vaccine administration, through state mandates, will successfully immunize the population and
create desired levels of herd immunity because such policies will be inclusive and accessible to all
segments of the population.
III. MANDATING THE HPV VACCINE IS SOUND HEALTH POLICY
Though the medical community has reached a consensus on the necessity of widespread
vaccinations, the HPV debate remains a deeply fraught social issue because it is implicated in
controversial topics, such as vaccine safety, parental autonomy and adolescent sexuality. 131 In
order to mandate the HPV vaccination, states will have to include the vaccine in the list of
required vaccinations for school attendance. Studies have proven that school mandates are highly
effective at immunizing the population because school-related laws are influential, respected, and
followed.132 Proponents of mandating the HPV vaccination emphasize issues of herd immunity
and achieving universal coverage across all sexual orientations and socioeconomic groups. 133
Opponents of an HPV vaccination mandate cite issues of unnecessary promotion and approval of
adolescent sexual activity, abrogation of parental autonomy, and the lack of constitutional support
because HPV is a sexually transmitted disease, making it different than other vaccines. 134 To see
how these arguments have played out in the past, the next section will examine the development
of vaccination policies for another disease: Hepatitis B.
A. The Hepatitis B Vaccine as Precedent
The Hepatitis B vaccine has been cited as precedent for an HPV vaccination mandate. 135
130

Kim, supra note 61, at 849.

131

James Colgrove et al., HPV Mandates—Lawmaking Amid Political and Scientific Controversy, 363 NEW
ENG. J. MED. 785, 785 (2010).
132
Alan R. Hinman et al., Childhood Immunizations: Laws that Work, 20 J. L. MED. & ETHICS 122, 122
(2002); see also Julie Y. Morita et al., Effect of a School-Entry Vaccination Requirement on Racial and Ethnic Disparities
in Hepatitis B Immunization Coverage Levels Among Public School Students, 121 PEDIATRICS e547, e550–51 (2008)
(asserting that school mandated vaccinations for Hepatitis B created more equitable coverage among middle school
students of color).
133

See Law, supra note 18, at 1764 (arguing that HPV vaccination should be mandated in schools in order
to protect the long-term interests of women, low-income people, and racial minorities); see also Wood, supra note 9, at 34
(stating that a universal HPV vaccine may be the only way to ensure that low-income Hispanic and African American
women will have access to the vaccine).
134

See Wood, supra note 9, at 34; Colgrove et al., supra note 131, at 787 (stating that some social
conservatives object to mandatory HPV vaccination policies because they believe the policies undermine abstinence
education efforts); Javitt et al., supra note 20, at 387–93 (illustrating the view that mandatory HPV vaccinations violate
principles of parental autonomy); Law, supra note 18, at 1767–71 (stating that courts are unlikely to interfere with parental
autonomy with regard to the HPV vaccine because the risk of contracting cancer is statistical and remote); see also Susan
Levine, Parents Question HPV Vaccine, WASH. POST, Mar. 4, 2007, at C1 (exploring whether mandatory HPV
vaccination policies encourage adolescents to be promiscuous or intrude upon principles of parental autonomy).
135

See, e.g., Rothman & Rothman, supra note 122, at 782–83; Gillian Haber et al., The HPV Vaccine

Published by Penn Law: Legal Scholarship Repository, 2012

CHERKIN_FINAL[1].DOCX (DO NOT DELETE)

490

4/30/2012 5:33 PM

UNIV. OF PENNSYLVANIA JOURNAL OF LAW AND SOCIAL CHANGE

[Vol. 15

Legal scholars cite it in support of the constitutionality of a HPV mandate, 136 and medical
professionals cite it in support of universal coverage. 137 Hepatitis B is similar to HPV in that it is
a highly contagious sexually transmitted disease. 138 The experiences of the Hepatitis B vaccine
shed light on three specific issues impacting the success of the HPV vaccine: (1) universality; (2)
financing; and (3) sexuality.
Similar to the HPV vaccine, the Hepatitis B vaccine was initially targeted at only a
segment of the population when it was first approved in the 1980s.139 However, as discussed in
Part II, policymakers soon realized that vaccinating only part of the population did not reduce the
prevalence of the disease, and incidence of the disease actually increased between the 1980s and
1990s.140 It was not until the vaccine was recommended for universal coverage in infants and
adolescents by the ACIP in the 1990s that coverage rates began to increase, thus decreasing the
prevalence of the disease.141 Of the Hepatitis B vaccination policies, vaccine expert James
Colgrove asserted:
[B]ecause the [Hepatitis B] virus spreads primarily among sexually active
people and injection-drug users, some parents argued that the vaccine should be
given only to those groups rather than to all children. Such targeting of the
vaccine, however, proved to be less effective than universal vaccination in
reducing the incidence of the disease.142
Funding was a concern for the Hepatitis B vaccine and affected its uptake in the general
population. Between the initial introduction of the Hepatitis B vaccine in the 1980s and an
upsurge in coverage by the end of the 1990s, the federal government enacted the Vaccines for
Children program, mentioned earlier.143 This program is credited with providing the funding
necessary to support universal coverage of the Hepatitis B vaccination.144

Controversy, 20 J. PEDIATRIC & ADOLESCENT GYNECOLOGY 325, 326 (2007) (“[W]e have the precedent of school-entry
mandates for hepatitis B virus (HBV) vaccine, including „catch-up‟ requirements in most states for middle school entry.
Like HPV, HBV is overwhelmingly a sexually transmitted infection (STI), with few documented cases of casual contact
transmission.”).
136
See, e.g., Kyra R. Wagoner, Comment, Mandating the Gardasil Vaccine: A Constitutional Analysis, 5
IND. HEALTH L. REV. 403 (2008); Law, supra note 18, at 1757.
137

See, e.g., Haber et al., supra note 135; see also Rothman & Rothman, supra note 122.

138

See Hepatitis B Facts for Health Care Professionals, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#b1 (last visited Apr. 10, 2012); see also Monique H. Lawrence & Mark A
Goldstein, Hepatitis B Immunization in Adolescents, 17 J. ADOLESCENT HEALTH 234, 235 (1995) (establishing that one of
the risks for children, in addition to risky sexual behavior, was that the disease could be passed through cuts and scrapes,
as well as through shared razors and toothbrushes). For an analysis of the Hepatitis B vaccine and use among adolescents
see Susan L. Rosenthal et al., Hepatitis B Vaccine Acceptance Among Adolescents and Their Parents, 17 J. ADOLESCENT
HEALTH 248, 248 (1995).
139

Rothman & Rothman, supra note 122, at 782.

140

Id.; Lawrence & Goldstein, supra note 138, at 243–35.

141

See Rothman & Rothman, supra note 122, at 782–83.

142

James Colgrove, The Ethics and Polices of a Compulsory HPV Vaccination, 355 NEW ENG. J. MED.
2389, 2390 (2006).
143

Rothman & Rothman, supra note 122, at 783; Rosenthal et al., supra note 138, at 254.

144

Rothman & Rothman, supra note 122, at 783.
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Unlike the HPV vaccine, controversy did not surround the Hepatitis B vaccine. 145
Although some parents and providers opposed the universal application of the Hepatitis B
vaccination, the opposition was mostly in regards to cost and funding, and less about adolescent
sexuality.146 There is significant public controversy over implementing the HPV vaccination,
however, due largely to federal support of abstinence-only education and the rise of the Religious
Right in the 1990s and 2000s, which was lacking when the Hepatitis B vaccine was recommended
for universal use.147
Current federal policies, in addition to the change in political climate, have affected the
success of the HPV vaccine, differentiating its experience on the market from the Hepatitis B
vaccine. First, the Hepatitis B vaccination was recommended for universal use almost ten years
after it was introduced on the market. Contrarily, the HPV vaccine has only been on the market
for five years to date. Second, implementing the Hepatitis B vaccine included a struggle for
federal funding, which led to the creation of Vaccines for Children. This program already covers
the HPV vaccination for both males and females, and so federal funding is not an issue for the
HPV vaccine. Cost, nonetheless, is an issue for the HPV vaccine; Gardasil is one of the most
expensive vaccines recommended by the ACIP.148 However, programs like Vaccines for Children
allow those who cannot afford the vaccine to get inoculated. Additionally, Merck & Co. offers
the vaccine for free to women over age eighteen who do not qualify for the Vaccines for Children
program.149 Third, the political climate has become more protective of adolescent sexuality since
the introduction of the Hepatitis B vaccine. The experiences of the Hepatitis B vaccine
demonstrate that targeting only a specific segment of the population for vaccination will be
unsuccessful in reducing the disease‟s prevalence, even though the disease is sexually transmitted.
Rather than repeating the mistakes of the Hepatitis B vaccine, policymakers should mandate
universal coverage now to prevent further increased incidents of genital cancers. The power to
lower cancer rates in the United States is in the hands of policymakers. How will they act?
B.

It is Constitutional to Mandate

In its seminal decision on mandatory vaccinations, the Supreme Court ruled in Jacobson
145
Monica J. Casper & Laura M. Carpenter, Sex, Drugs, and Politics: The HPV Vaccine for Cervical
Cancer, 30 SOCIOLOGY OF HEALTH & ILLNESS 886, 896 (2008) (citing to a conversation the authors had with James
Colgrove).
146

Gary L. Freed et al., Universal Hepatitis B Immunization of Infants: Reactions from Pediatricians and
Family Physicians Over Time, 93 PEDIATRICS 747, 750–51 (1994); Rosenthal et al., supra note 138, at 254 (“Previous
studies examining physician attitudes towards hepatitis B immunization has shown that some practitioners have chosen not
to implement AAP recommendations because of concerns about the hepatitis B vaccination policy, particularly the
financial burden.”).
For a succinct history of the rise of abstinence only education, see Danielle LeClair, Comment, Let’s Talk
About Sex Honestly: Why Federal Abstinence-Only-Until-Marriage Education Programs Discriminate Against Girls, are
Bad Policy, and Why They Should be Overturned, 21 WIS. WOMEN‟S L. J. 291, 293–99 (2006); see also Kelly Keefe &
Amber Oleson, A New Twist on the Birds and the Bees: Adolescent Female Sexuality and the Debates Surrounding Access
to Birth Control, Comprehensive Sex Education, and the HPV Vaccine, 28 CHILD. LEGAL RTS. J. 13, 20–22 (2008). For a
short discussion of the rise of the Religious Right in connection with the HPV vaccine, see Casper & Carpenter, supra
note 145, at 892–93.
147

148

Mendenhall, supra note 125, at 49.

149

Merck Vaccine Patient Assistance Program, MERCK, http://www.merck.com/merckhelps/vaccines/home.
html (last visited Apr. 10, 2012).
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v. Commonwealth of Massachusetts in 1905 that it is within a state‟s police power to mandate
vaccinations, as long as it is “for the common good, for the protection, safety, prosperity, and
happiness of the people.”150 In Jacobson, a citizen refused to get the state-mandated smallpox
vaccination.151 The Court held that it was within the power of the Massachusetts legislature to
protect the commonwealth from a “disease which threatens the safety of its members.”152 This
power is not unlimited, but must serve a “real or substantial relation” to public health and
safety.153 States thus have a constitutional right to mandate a vaccination if a public health
necessity exists and the vaccination has a reasonable relationship to that necessity. 154
States are allowed to mandate vaccinations for children as a condition of school
attendance.155 In 1922, the Supreme Court in Zucht v. King upheld a local ordinance requiring
vaccinations for school attendance as a valid exercise of state power due to the unique public
health concern of a school setting, where children can easily communicate diseases. 156 Currently,
state-mandated vaccinations for school attendance are based on ACIP recommendations157 for
certain highly contagious communicable diseases, including influenza, chicken pox,
meningococcus, polio, and measles. 158 State-mandated vaccinations have been highly effective in
preventing outbreaks of the above-mentioned diseases, and studies show that outbreaks tend to
occur in communities where vaccination exemptions are common. 159 In general, school
vaccination mandates are viewed positively as an efficient means to vaccinate the population, and
are seen as beneficial to society as a whole.
Opponents of a HPV vaccination mandate argue that such a mandate is unconstitutional
because HPV is not an airborne disease transmitted in a school setting. 160 These opponents argue
that other diseases falling under state mandates for school attendance meet Jacobson‟s
reasonableness requirement because “[a]ll children who attend school are equally at risk of both
transmitting and contracting” these highly contagious diseases and as a result “a clear relationship
exists between conditioning school attendance on vaccination and the avoidance of the spread of
infectious disease within the school environment.” 161 Additionally, it has been argued that HPV
does not meet the Jacobson test because HPV and cervical cancer are not a “widespread
epidemic” like smallpox at the time of Jacobson.
Nonetheless, the HPV vaccine does meet the Jacobson test. A state-mandated HPV

150

197 U.S. 11, 27 (internal citations omitted).

151

Id. at 13.

152

Id. at 27.

153

Id. at 31.

154

Tracey Solomon Dowling, Note, Mandating a Human Papillomavirus Vaccine: An Investigation into
Whether Such Legislation is Constitutional and Prudent, 34 AM. J.L. & MED. 65, 66 (2008).
155
James G. Hodge, Jr. & Lawrence O. Gostin, School Vaccination Requirements: Historical, Social and
Legal Perspectives, 90 KY. L.J. 831, 857–58 (2001-2002) (“Despite the mandatory nature of compulsory school
vaccination laws, the state‟s power to require children to be vaccinated as a condition of school entrance has been widely
accepted and judicially sanctioned.”).
156

260 U.S. 174, 177 (1922).

157

Oleson, supra note 72, at 66.

158

Javitt et al., supra note 20, at 389.

159

Hinman et al., supra note 132, at 125.

160

Javitt et al., supra note 20, at 389.

161

Id.
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vaccination is constitutional because it serves the rational purpose of working to achieve a health
policy goal.162 HPV is a pressing health issue, and as such, vaccination is a public health
necessity: “[P]eople infected with HPV are personally at risk of various diseases and . . . can
easily transmit the virus and risk of disease to others.” 163 Additionally, the vaccine has a
reasonable relationship to public necessity because it has been proven highly efficacious, and
thus, will benefit the population. It is true that HPV is not an “infectious airborne disease,” 164 but
it is, nevertheless, highly contagious. 165 Although HPV is not necessarily communicated in a
school setting, the Hepatitis B vaccine experience suggests that school-attendance mandates can
be applied to sexually transmitted diseases. Mandating the vaccination is the most effective way
to immunize the population and reduce the prevalence of HPV-related cancers and infections in
the United States. It is therefore constitutional and within a state‟s power to mandate the HPV
vaccination for school attendance.
C.

The Benefits Outweigh the Risks

There were relatively few adverse events connected to the vaccine during clinical drug
trials and very few side effects of the vaccine reported since it was first administered in 2006. 166
Most adverse events related to the vaccine in clinical trials involved pain at the injection site or
fever.167 In studies conducted on females, there were very few serious adverse events. In one
study of 2,673 female participants, there was one serious adverse incident, 168 and in a second
study of 6,019 female participants there were seven serious adverse incidents.169 In this second
study, conducted by Members of the Females United to Unilaterally Reduce Endo/Ectocervical
Disease (FUTURE) II Study Group, the participants were followed for up to three years after
administration of the vaccine, and within this extended period there was only a .01% risk of any
serious adverse incident.170 There were fewer adverse incidents connected to the vaccine reported
in studies of males in comparison to studies of females, which researchers attribute to the higher
levels of muscle mass in males at injection sites. 171 For the male-only studies, most adverse
events reported in trials were not serious and, similar to the female-only trials, related to pain at
the injection site or fever.172 In one study of male participants, there were no serious adverse
162
Law, supra note 18, at 1753–54 (arguing that HPV as a highly contagious disease and as such meets the
principles set forth in Jacobson).
163

Id. at 1753.

164

Lawrence O. Gostin & Catherine D. DeAngelis, Mandatory HPV Vaccine: Public Health vs. Private
Wealth, 297 JAMA 1921, 1922 (2007).
165

Law, supra note 18, at 1754.

166

Zimet, Potential Barriers, supra note 55, at 391.

167

See Barbara A. Slade et al., Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus
Recombinant Vaccine, 302 JAMA 750 (2009) (describing physical reactions to the vaccine injection); see generally
Garland et al., supra note 63 (providing an analysis of an HPV vaccine trial); The FUTURE II Study Group, Quadrivalent
Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions, 356 NEW ENG. J. MED. 1915 (2007)
[hereinafter The FUTURE II Study Group] (providing procedural information of an HPV vaccine trial).
168

Garland et al., supra note 63, at 1934–35, 1940.

169

The FUTURE II Study Group, supra note 167, at 1924.

170

Id.

171

Giuliano et al., HPV in Males, supra note 67, at 409.

172

Id.
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events reported.173
After a vaccine goes to market, all adverse incidents are reported to the Vaccine Adverse
Event Reporting System (VAERS). VAERS is co-sponsored by the FDA and the CDC and
monitors vaccines after they have been administered to the population. 174 VAERS monitors
vaccines by receiving reports about adverse events from providers, manufacturers, and
individuals.175 VAERS is described as “a national, voluntary, passive surveillance system.” 176 A
recent study on VAERS reports about the HPV vaccine demonstrated that significant adverse
events are not associated with the vaccine. 177 Researchers stated: “Our review of 12,424 reports
of [reported adverse events] following receipt of [the] HPV [vaccine] after licensure found that
most did not meet the FDA definition of serious.” 178 The vaccine will continue to be monitored
by VAERS, but current studies do show that the vaccine is safe.
Researchers still do not know how long the effectiveness of the vaccine will last, and if
those vaccinated will need a booster shot at some point. Studies comparing the epidemiology of
the vaccine to that of the Hepatitis B vaccine have been conducted in order to examine the
potential long-term effectiveness of the vaccine. 179 Studies of the Hepatitis B vaccine reveal that
the long-term immunity of the vaccine is connected to its ability to induce immune memory in the
body.180 Clinical trials of the HPV vaccine demonstrate that the drug is effective in inducing
immune memory for at least up to five years,181 and that the development of the immune memory
is similar to that of Hepatitis B.
The fact that the long-term effectiveness of the vaccine is unknown is not a reason to
discount the benefits and relatively low risks of the vaccine. There are many vaccines currently
administered that require subsequent booster shots.182 In a 2007 article on the risk and benefits of
HPV, New York Times Medical Health Specialist Jane E. Brody asserted in response to an inquiry
about the long-term safety and efficacy of the vaccine: “[W]e do have at least five years of safety
data that include no hints of long-term risks or waning effectiveness. But if the vaccine should
begin to lose potency over time, that could easily be remedied by a booster shot.” 183 Current data
shows that the vaccine is highly effective and the risks of adverse events are very low. Thus, the
173

Id.

174

VACCINE ADVERSE EVENT REPORTING SYSTEM, http://vaers.hhs.gov/index (last visited Apr. 10, 2012).

175

About the VAERS Program, VACCINE ADVERSE EVENT REPORTING SYSTEM, http://vaers.hhs.gov
/about/index (last visited Apr. 10, 2012).
176

See generally Slade et al., supra note 167 (describing minimal adverse physical reactions post-

vaccination).
177

Id. at 755.

178

Id.

179

See, e.g., Kevin A. Ault, Long-Term Efficacy of the Human Papillomavirus Vaccination, 107
GYNECOLOGIC ONCOLOGY S27, S29 (2007) (comparing Hepatitis B and HPV vaccine studies and finding that long-term
vaccine efficiency is dependent on a “robust immune memory”).
180

Id.

181

Id. at S29–30.

182

See Tetanus (Lockjaw) Vaccination, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm (last visited Apr. 10, 2012) (discussing the need for a tetanus
booster every ten years); Pertussis (Whooping Cough) Vaccination, CTRS. FOR DISEASE CONTROL & PREVENTION,
http://www.cdc.gov/vaccines/vpd-vac/pertussis/default.htm (last visited Apr. 10, 2012) (discussing the booster shot for
Pertussis, Tetanus, and Diptheria).
183

Jane E. Brody, HPV Vaccine: Few Risks, Many Benefits, N.Y. TIMES, May 15, 2007, at F7.
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benefits of the HPV vaccine clearly outweigh the risks, and the potential for vaccine risks, or even
a reduction in immunity, should not weigh against mandating the vaccine for school attendance.
D.

Good Health Policy

Mandating the HPV vaccine is sound health policy. A universal mandate will allow for
timely coverage, broader education and higher levels of awareness, and prevent stigmatization of
MSM and the exclusion of WSW. Additionally, a universal vaccine will create higher levels of
immunity throughout the population.
Education is key to the success of the HPV vaccine. Studies demonstrate that once
awareness of HPV is increased, there is typically a desire to obtain the HPV vaccine. 184 However,
males are significantly less knowledgeable about HPV and the health consequences of HPV than
females.185 Specifically, studies show that there is limited knowledge of HPV among MSM. 186 In
one study of gay and bisexual males, although very well aware that HPV was an STI, the
participants often did not know that HPV could lead to genital warts, and even fewer knew that
HPV could cause anal and penile cancer.187 Although the dearth of knowledge among males in
general can be partly attributed to the focus of Merck & Co.‟s advertising campaign on females
and parents of females,188 the lack of knowledge among males, regardless of sexuality, is
alarming. Scholars indicate that without mandating the vaccination, it will be hard to encourage
males to get vaccinated at a young age because the parents of males have been unengaged in
conversations around HPV and the vaccine.189
Abstinence-only education across the United States prevents an increase in STI
education. Although conservatives argue that mandating the HPV vaccination will undermine
efforts made by abstinence-only education and cause more adolescents to engage in sexual
activities,190 this argument is built on a faulty foundation because countless studies have proven
that abstinence-only education does not prevent adolescents from engaging in sexual activities. 191
In fact, abstinence-only education neither delays “the age of sexual initiation, nor . . . decrease[s]
the number of sexual encounters” adolescents have. 192 It is argued that abstinence-only education
is actually dangerous for adolescents because it “leav[es] them perilously unaware, or even
misinformed about genuine probable risks” of sex by not teaching about STIs or contraception. 193
184
Monica Christine R. Nandwani, Men’s Knowledge of the Human Papillomavirus Vaccine, 35 NURSE
PRACTITIONER 32, 38 (2010) (discussing a correlation between HPV awareness and an increased vaccination intent in
men); see also Reiter et al., supra note 81, at 199 (observing that approximately 74% of male study participants were
willing to get the HPV vaccine).
185

Zimet & Rosenthal, supra note 109, at S26; Nandwani, supra note 184, at 36.

186

Reiter et al., supra note 81, at 200.

187

Id. at 199.

188

Nandwani, supra note 184, at 37.

189

Liddon et al., supra note 75, at 2.

190

Wood, supra note 9, at 34; Colgrove et al., supra note 131, at 787.

191

Bleakley et al., supra note 10, at 1152.

192

R. Alta Charo, Politics, Parents, and Prophylaxis—Mandating HPV Vaccination in the United States,
356 NEW ENG. J. MED. 1905, 1907 (2007); see also Michelle Fine & Sara I. McClelland, Sexuality Education and Desire:
Still Missing After all These Years, 76 HARV. EDUC. REV. 297, 312 (2006) (discussing findings that abstinence-only
programs do not delay intercourse).
193

Globerson, supra note 18, at 89.
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If knowledge is key to HPV administration and uptake in the population, then these programs
create a concrete barrier to the reduction of HPV by failing to educate adolescents about STIs.
STIs in general, and HPV in particular, are highly prevalent among adolescents and
young adults.194 Studies demonstrate that HPV infection occurs at a higher rate right after an
individual‟s sexual debut.195 Studies show that by age fourteen or fifteen, a significant percentage
of adolescents have engaged in sexual activities and about twenty-five percent of adolescents
have engaged in vaginal sex.196 It is argued that in states with high levels of abstinence-only
education, adolescents are less likely to engage in vaginal or anal sex but are choosing oral sex at
higher rates.197 Due to the rigidity of the abstinence-only education they are receiving, these teens
are unaware of the STI risks associated with oral sex, and are unknowingly increasing their risk
levels for HPV and other STIs that can be transmitted through oral sex. 198 One study stated,
“HPV DNA has been reported in approximately 20% of women who have never had vaginal
intercourse, suggesting that abstaining from penetrative intercourse is not completely protective
against infection.”199 Abstinence-only education fails to educate adolescents about STI risks from
sexual activity, and thus adolescents remain highly susceptible to HPV transmission. Researchers
argue that only comprehensive sexual education, which speaks to the risks of STIs and teaches
adolescents about contraception and safe sex, will reduce the high prevalence of sexually
transmitted diseases among adolescents.200
Opponents of the HPV vaccination argue that vaccinating adolescents for a sexually
transmitted disease will give them a false sense of security and increase sexual activities.201
However, this argument has never been proven to be correct. A sociologist from the CDC was
cited in the New England Journal of Medicine for the proposition that “fear of sexually
transmitted diseases has not been a major motivation for adolescents to abstain from sex [] and the
availability of condoms and emergency contraception has not had measurable effects on the
frequency of unsafe behavior.”202 Comparisons to condom availability are made to refute the
argument that the HPV vaccination will increase adolescent sexual activities.203 The availability
of condoms in schools did not change the number of adolescents having sex, but rather, according
to CDC studies, made adolescent sex safer by increasing condom usage. 204 Additionally, studies
194
See, e.g., Susan L. Rosenthal & Lawrence R. Stanberry, Parental Acceptability of Vaccines for Sexually
Transmitted Infections, 159 ARCHIVES OF PEDIATRIC & ADOLESCENT MED. 190, 190 (2005) (“About half of the 18 million
new STI cases in 2000 were among those between 15 and 25 years of age.”).
195

Forhan et al., supra note 103, at 1509–10.

196

Gregory D. Zimet, Improving Adolescent Health: Focus on HPV Vaccine Acceptance, 37 J.
ADOLESCENT HEALTH S17, S17 (2005); Bleakley et al., supra note 10, at 1151.
197

Globerson, supra note 18, at 91.

198

Id.

199

Villa, supra note 97, at S1/23 (citing Catherine Ley et al., Determinants of Genital Human
Papillomavirus Infection in Young Women, 83 J. NAT‟L CANCER INST. 997, 1003 (1991)).
200

Forhan et al., supra note 103, at 1510.

201

See generally Gibbs, supra note 9 (explaining that some opponents of the vaccination believe it will be
detrimental to the sexual activities of teenagers); see also Globerson, supra note 18, at 89; Wood, supra note 9, at 34.
202

Robert Steinbrook, The Potential of Human Papillomavirus Vaccines, 354 NEW ENG. J. MED. 1109, 1112
(2006) (citing the opinion of Nicole Liddon, a CDC sociologist).
203

Monk & Wiley, supra note 10, at 421.

204

See id. (asserting that the HPV vaccine will not negatively affect teenage sexual relations since the
availability of condoms has not).
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have shown that access to emergency contraception has not increased adolescent sex or spurred
younger adolescents to engage in sex. 205 A 2006 article in the Journal of Obstetrics and
Gynecology stated the point perfectly: “Seat belts do not cause reckless driving, tetanus shots do
not cause children to seek out rusty nails, and the [H]epatitis B vaccination has not altered sexual
practices.”206
An additional argument against mandating the vaccination is that making it a
requirement for school attendance undercuts parental autonomy because mandatory vaccinations
necessarily impinge on a parent‟s decision to vaccinate his or her child. The Supreme Court has
stated repeatedly that parents have the fundamental right to control their child‟s upbringing. 207 It
has been argued that a parent‟s fundamental right to direct a child‟s upbringing extends to issues
of birth control, sex, and the HPV vaccination.208 However, parental autonomy with respect to
one‟s children is not limitless. 209 Parental decisions based on religious beliefs or moral values are
not allowed to subject children to harm. 210 In 1944, the Supreme Court stated in Prince v.
Massachusetts that “[p]arents may be free to become martyrs themselves. But it does not follow
that they are free, in identical circumstances, to make martyrs of their children . . . .”211 Parental
autonomy can be limited by a mandated HPV vaccination, as it is with other school-mandated
vaccinations. HPV vaccine proponents should focus on the universal acquisition of the disease
and its serious negative health consequences in order to encourage parental acceptance of the
vaccine.
Some argue that legislation with wide parental exemptions is the only appropriate way to
enact HPV vaccination legislation.212 Although not constitutionally required to do so, states can
allow exemptions to vaccination mandates, 213 and states can choose not to allow exemptions. 214
All states must have medical exemptions,215 most have religious exemptions,216 and a small
number allow for philosophical exemptions. 217 However, in Prince v. Massachusetts, the
Supreme Court asserted that religious rights can be preempted when societal values and welfare
are threatened: “Thus, [a parent] cannot claim freedom from compulsory vaccination for the child
more than for himself on religious grounds. The right to practice religion freely does not include
liberty to expose the community or the child to communicable disease or the latter to ill health or

205

See id. (citing a 2005 study on the effects of emergency contraception on sexual practices).

206

Id. at 421.

207

See supra note 5.

208

Keefe & Oleson, supra note 147, at 14.

209

Prince, v. Massachusetts, 321 U.S. 158, 166 (1944).

210

See id. (arguing that the state may infringe upon a guardian‟s decision pertaining to her child if it harms

211

Id. at 169.

212

See Law, supra note 18, at 1768; see also Wood, supra note 9, at 34.

213

Law, supra note 18, at 1768.

the child).

214

See Workman v. Mingo Cnty. Sch., 667 F. Supp. 2d 679, 689 (S.D. W. Va. 2009) (citing case law from
other states and district courts that do not allow exemptions for vaccines).
215

Law, supra note 18, at 1765.

216

See Anthony Ciolli, Religious & Philosophical Exemptions to Mandatory School Vaccinations: Who
Should Bear the Costs to Society, 74 MO. L. REV. 287, 287 (2009) (asserting that West Virginia and Mississippi are the
only two states that do not allow religious exemptions for mandatory vaccinations).
217

Dowling, supra note 154, at 70.
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death.”218
There are two main arguments against allowing exemptions for an HPV vaccination
mandate. First, allowing exemptions prevents successful herd immunity. 219 Unvaccinated
children and adolescents are a potential threat to the general population, and specifically, if they
are clustered together, are a threat to themselves because there is clear evidence that with less
stringent vaccination requirements, there are more outbreaks of “vaccine preventable
infections.”220 Second, parental decisions and adolescents‟ sexual choices are not necessarily in
sync. A parent‟s decision to not vaccinate his or her child might put that adolescent at risk,
because regardless of what a parent believes, it is the adolescent‟s decision whether or not to have
sex.221 According to a recent article in Pediatrics, “Because a substantial proportion of female
adolescents acquire HPV infection soon after sexual initiation and parents typically fail to predict
the timing of their daughters‟ sexual initiation, routine vaccination of preadolescent girls . . . is of
critical importance.”222 Mandating the HPV vaccination will protect all males and females from
dangerous health burdens, not for the sake of their parents, or based on their parents‟ religious
beliefs,223 but for their own sake. Thus, not only is it constitutional to mandate the HPV
vaccination for school attendance, but it is also sound health policy to do so.
IV. CONCLUSION
As of July 2011, only Virginia and Washington D.C. had passed legislation mandating
the vaccination for school attendance. 224 Both laws have widely applicable opt-out provisions,
which make it easy for parents to choose not to vaccinate their adolescents. 225 In 2007, there were
twenty states considering similar legislation, none of which were passed. 226 The failure of these
laws is attributed to the power of moral conservatives and the Religious Right. 227 However, the
tide is shifting. There were significantly more bills proposed in state legislatures between 2009
and 2010 than in previous years. In the past two years, states have increasingly enacted

218

Prince, 321 U.S. at 166–68.

219

Wagoner, supra note 136, at 435.

220

Zimet, Potential Barriers, supra note 55, at 392; see also Wagoner, supra note 136, at 435–36.

221

Renee Gerber, Mandatory Cervical Cancer Vaccinations, 35 J.L. MED. & ETHICS 495, 496 (2007).

222

Forhan et al., supra note 103, at 1510.

223

Gerber, supra note 221, at 495.

224

D.C. CODE § 7-1651.04 (b)(1)(B)(iii) (2008); VA. CODE ANN. § 32.1-46 (D)(3) (2008); see also HPV
Vaccine, NATIONAL CONFERENCE OF STATE LEGISLATURES, http://www.ncsl.org/default.aspx?tabid=14381 (last visited
Apr. 10, 2012).
225

VA. CODE ANN. § 32.1-46 (D)(3) (2008).

Because the human papillomavirus is not communicable in a school setting, a parent or guardian, at
the parent‟s or guardian‟s sole discretion, may elect for the parent‟s or guardian‟s child not to
receive the human papillomavirus vaccine, after having reviewed materials describing the link
between the human papillomavirus and cervical cancer approved for such use by the Board.
Id. D.C. CODE § 7-1651.04(b)(1)(B)(i) (2008) (“The parent or legal guardian [can object] in good faith [if] . . . the
vaccination would violate his or her religious beliefs.”); D.C. CODE § 7-1651.04(b)(1)(B)(iii) (2008) (“The parent or legal
guardian, in his or her discretion, [can elect] to opt out of the HPV vaccination program, for any reason.”).
226

Casper & Carpenter, supra note 145, at 894.

227

Id. at 892.
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legislation mandating insurance coverage for the vaccine, funding the vaccine for uninsured or
underinsured adolescents, or requiring education on the dangers of HPV. This increase in
legislative activity signals a recognition by policymakers of the importance of the HPV
vaccine.228 However, there is more work to be done. In addition to legislative efforts, more costeffectiveness analyses need to be completed to demonstrate that it is cost-effective to vaccinate
the entire population. More studies need to be completed on the long-term efficacy of the
vaccine. And education initiatives are necessary to educate the population on the dangers of HPV
and the benefits of the vaccine.
A 2010 study from Australia demonstrated high efficacy of the vaccine in reducing rates
of genital warts.229 In April 2007, the Australian government started a program aimed at
vaccinating all girls at age twelve. 230 The program also included a catch-up vaccination for all
females over the age of twelve. 231 Researchers stated that prior to the introduction of the
vaccination, rates of genital warts stayed relatively stable; however, after the government-initiated
program, rates of genital warts among females dropped significantly. 232 The study highlighted the
high efficacy of the vaccine. This Australian study is the first non-clinical study of a
comprehensive vaccination program, and demonstrated promising results for such a program in
the United States.233
In the United States, there are larger societal issues implicated by the HPV vaccine
controversy. Abstinence-only education is not working and is putting adolescents at risk.
Comprehensive sexual education is necessary; federal dollars should be spent on educating teens
about safe sex and contraception. Discourses on the sexual health of men who have sex with
men, and women who have sex with women need to be included in sexual education classes as
well. The heterosexual focus of medical conversations needs to be redirected, and health policies,
particularly sexual health polices, need to focus on all members of the population. The HPV
vaccine will benefit the public, and will reduce the prevalence of certain cancers in the United
States. Mandating the vaccine will efficiently and effectively immunize the population and be
beneficial to public health. In the case of HPV, inclusion is key, so that all members of society
are included, and no group is left out.
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